ArticleCytotechnology2025
A web-based pharmacological approach to the mechanism of action of Radix Bupleuri in the treatment of chronic atrophic gastritis.
Article in Cytotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radix Bupleuri (RB) is used as a traditional Chinese medicine for treating gastric disorders. However, the active components and pharmacological targets of RB are unknown. In this study, we aimed to reveal the pharmacological effects of RB on gastritis by combining a rat model and a network pharmacology approach. The results showed that quercetin was the most activate ingredient in the treatment of chronic atrophic gastritis (CAG). The molecular docking results showed that RB had a strong affinity with TNF. In vivo and in vitro experiments showed that RB alleviated MNNG-induced gastritis by inhibiting the TNF-α/NF-κB signaling pathway. Through network pharmacology, molecular docking, and in vitro and in vivo experiments, the mechanisms and potential effects of RB on CAG were demonstrated, and a theoretical basis for RB in the treatment of CAG was provided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.